BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2021 8:15:21 AM | Browse: 716 | Download: 1632
 |
Received |
|
2021-02-15 07:49 |
|
Peer-Review Started |
|
2021-02-15 07:54 |
|
First Decision by Editorial Office Director |
|
2021-03-30 02:29 |
|
Return for Revision |
|
2021-03-30 02:29 |
|
Revised |
|
2021-04-12 18:36 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-19 03:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-19 07:56 |
|
Articles in Press |
|
2021-07-19 07:56 |
|
Edit the Manuscript by Language Editor |
|
2021-07-28 01:26 |
|
Typeset the Manuscript |
|
2021-09-02 01:46 |
|
Publish the Manuscript Online |
|
2021-09-07 08:15 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ayan Roy, Jayaprakash Sahoo, Niya Narayanan, Chandhana Merugu, Sadishkumar Kamalanathan and Dukhabandhu Naik |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jayaprakash Sahoo, MD, Additional Professor, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Room No. 5444, 4th Floor, Super Specialty Block, Puducherry 605006, India. jppgi@yahoo.com |
| Key Words |
Autoimmune disease; Bullous pemphigoid; Diabetes; Dipeptidyl peptidase-4 inhibitors; Gliptins; Inflammation |
| Core Tip |
Dipeptidyl peptidase-4 (DPP-4) has an important role in the function of the immune system. DPP-4 inhibitors (DPP-4i) are an important drug class for the management of type 2 diabetes mellitus. This group of drugs can have a diverse effect on the immune modulation. Recently, certain autoimmune diseases are described with the use of DPP-4i, particularly bullous pemphigoid. Clinicians should be aware of this association and take appropriate action if such an adverse event takes place. |
| Publish Date |
2021-09-07 08:15 |
| Citation |
Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes 2021; 12(9): 1426-1441 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i9/1426.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i9.1426 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
